5 research outputs found
Oxidative stress parameters in Posttraumatic Stress Disorder risk group patients
Get PDFFunding Information: The research is supported by European Social Foundation co-financing: Project for Doctoral students support, at RĆ®ga StradiĆ²Ć° University (No. 2009/0147/1DP/1.1.2.1.2/09/IPIA/ VIAA/009). The views expressed in this article are those of the authors and do not reflect the official policy or position of the Latvian government, Latvian National Armed Forces, Medical Support Centre of Latvian National Armed Forces or any of the institutions with which the authors are affiliated. The authors state no conflict of interest. All authors read and approved the final manuscript.Increased excitotoxity in response to stressors leads to oxidative stress (OS) due to accumulation of excess reactive oxygen/nitrogen species. Neuronal membrane phospholipids are especially susceptible to oxidative damage, which alters signal transduction mechanisms. The Contingent of International Operations (CIO) has been subjected to various extreme stressors that could cause Posttraumatic Stress Disorder (PTSD). Former studies suggest that heterogeneity due to gender, race, age, nutritional condition and variable deployment factors and stressors produce challenges in studying these processes. The research aim was to assess OS levels in the PTSD risk group in CIO. In a prospective study, 143 participants who were Latvian CIO, regular personnel, males, Europeans, average age of 27.4, with the same tasks during the mission, were examined two months before and immediately after a six-month Peace Support Mission (PSM) in Afghanistan. PCL-M questionnaire, valid Latvian language "Military" version was used for PTSD evaluation. Glutathione peroxidase (GPx), superoxide dismutase (SOD) and lipid peroxidation intensity and malondialdehyde (MDA) as OS indicators in blood were determined. Data were processed using SPSS 20.0. The MDA baseline was 2.5582 Ī¼M, which after PSM increased by 24.36% (3.1815 Ī¼M). The GPx baseline was 8061.98 U/L, which after PSM decreased by 9.35% (7308.31 U/L). The SOD baseline was 1449.20 U/gHB, which after PSM increased by 2.89% (1491.03 U/gHB). The PTSD symptom severity (total PCL-M score) baseline was 22.90 points, which after PSM increased by 14.45% (26.21 points). The PTSD Prevalence rate (PR) baseline was 0.0357, which after PSM increased by 147.06% (0.0882). We conclude that there is positive correlation between increase of OS, PTSD symptoms severity level, and PTSD PR in a group of patients with risk of PTSD - CIO. PTSD PR depends on MDA intensity and OS severity. OS and increased free radical level beyond excitotoxity, is a possible causal factor for clinical manifestation of PTSD.publishersversionPeer reviewe
Combined medical treatment of chronic pancreatitis
Get PDFFunding Information: This study was supported by ESF project Nr. 2009/0147/1DP/1.1.2.1.2/09/IPIA/VIAA/009.The aim of the study was to determine the most effective medical treatment of patients with chronic pancreatitis, by using either pancreatin alone or in combination with proton pump inhibitor (PPI) or PPI and non-steroidal anti-inflammatory drug (NSAID). Patients with chronic pancreatitis, who did not require a surgical treatment, received medical treatment for a one-month period: 20 patients received pancreatin monotherapy; 48 patients were given a combination of pancreatin and PPI; 38 patients were treated with a combination of pancreatin, PPI and NSAID (PNP therapy group). In comparison with other groups, patients in the PNP therapy group showed improvement in body mass index, abdominal pain, bowel movements, chronic pancreatitis severity, as well as their quality of life assessment (p < 0.05). The combination of pancreatin, PPI and NSAID was the most effective among those applied in chronic pancreatitis patient treatment. A one-month long course of this therapy was safe and did not cause any significant adverse effects. The combination of pancreatin, PPI and NSAID for treatment of chronic pancreatitis can be recommended, as it is based on pathogenesis of the disease, effective, safe and economically advantageous.publishersversionPeer reviewe
Hroniska pankreatÄ«ta gaitas smaguma novÄrtÄÅ”ana un kombinÄtÄ medikamentozÄ terapija ar pankreatÄ«nu, protonu sÅ«kÅa inhibitoru un nesteroÄ«do pretiekaisuma lÄ«dzekli. Promocijas darba kopsavilkums
Full text linkPromotion work has been carried out at RÄ«ga StradiÅÅ” University (RSU) Department of Internal Diseases. Defence: on the 3rd of November, 2014 at 15.00 at an open meeting of Promotion Council of Medicine of RÄ«ga StradiÅÅ” University at the Hippocrates Lecture Theatre, in 16 Dzirciema Street, Riga.The aim of the given work is to develop new assessment methods of chronic pancreatitis (CP) clinical course severity and pancreas structural change severity, and using pancreatin as monotherapy and as combination with proton pump inhibitor (PPI), as well as a combination of pancreatin, PPI and NSAID in patients with CP, to figure out the most effective medication treatment way among the ones applied. In given prospective randomized controlled study in order to appraise CP clinical course and pancreas structural change severity, some special methods were developed ā Clinical pancreatic index (CPI) and Visual pancreatic index (VPI). In the study CPI and VPI were used for CP patients in case of medical treatment. Patients with CP not needing surgical or endoscopic treatment were divided in three groups, depending on the type of therapy: 1) pancreatin monotherapy group, 2) pancreatin and PPI combined therapy group and 3) pancreatin, PPI and NSAID combined therapy group. The analysis of study approved that CPI is an unbiased and a valid tool to apply for CP clinical course severity and medical treatment efficiency and prognosis assessment. In patients with CP, VPI represents pancreas structural change severity and may be useful for predicting a necessity in surgical treatment. The analysis of study results entitled to conclude that the combination of pancreatin, PPI and NSAID is the most effective in terms of improving CP clinical path and patientās quality of life, compared to pancreatin monotherapy and pancreatin combination with PPI. One month long pancreatin, PPI and NSAID combination therapy is safe for CP patients and does not cause significant side effects. This is the first CP study in Latvia and the world in which 1) the severity of CP clinical course and pancreas structural change severity are assessed integrally and quantitatively, 2) a combination of pancreatin, PPI and NSAID is used and assessed in terms of efficiency, 3) This is the first CP study in Latvia in which EORTC QLQ-C30 and QLQ-PAN26 were used to assess CP patient quality of life in case of medical treatment.The Doctoral Thesis was supported by the ESF co-financed project āSupport to doctoral students for obtaining the study program and acquiring the scientific degree at RÄ«ga StradiÅÅ” Universityā, agreement No. 2009/0147/1DP/1.1.2.1.2/09/IPIA/VIAA/009
Assessment of Chronic Pancreatitis Course Severity and Combined Medical Treatment Using Pancreatin, Proton Pump Inhibitor and Non-Steroidal Anti-Inflammatory Drug. Summary of the Doctoral Thesis
Full text linkPromocijas darbs izstrÄdÄts: RÄ«gas StradiÅa universitÄtes IekŔķīgo slimÄ«bu katedrÄ. AizstÄvÄÅ”ana: 2014. gada 3. novembrÄ« plkst. 15.00 RÄ«gas StradiÅa universitÄtes MedicÄ«nas promocijas padomes atklÄtÄ sÄdÄ RÄ«gÄ, Dzirciema ielÄ 16, HipokrÄta auditorijÄ.Darba mÄrÄ·is ā izstrÄdÄt jaunas hroniska pankreatÄ«ta (HP) klÄ«niskÄs gaitas smaguma un aizkuÅÄ£a dziedzera izmaiÅu smaguma novÄrtÄÅ”anas metodes un, lietojot pankreatÄ«nu monoterapijÄ un kombinÄcijÄ ar protonu sÅ«kÅa inhibitoru, kÄ arÄ« kombinÄjot pankreatÄ«nu, protonu sÅ«kÅa inhibitoru un nesteroÄ«do pretiekaisuma lÄ«dzekli pacientiem ar HP, noskaidrot efektÄ«vÄko no lietotÄs medikamentozÄs ÄrstÄÅ”anas variantiem. ProspektÄ«vÄ randomizÄtÄ kontrolÄtÄ pÄtÄ«jumÄ HP klÄ«niskÄs gaitas un ADz strukturÄlo pÄrmaiÅu smaguma novÄrtÄÅ”anai tika izstrÄdÄtas speciÄlas metodes, izmantojot klÄ«nisko pankreÄtisko indeksu (KPI) un vizuÄlo pankreÄtisko indeksu (VPI). PÄtÄ«juma gaitÄ KPI un VPI tika pielietotas slimniekiem ar HP medikamentozÄs terapijas gadÄ«jumÄ. Slimnieki ar HP, kuriem nebija nepiecieÅ”ama Ä·irurÄ£iskÄ un endoskopiskÄ ÄrstÄÅ”ana, tika sadalÄ«ti trijÄs grupÄs atkarÄ«bÄ no terapijas veida: 1) pankreatÄ«na monoterapijas grupa, 2) pankreatÄ«na un protonu sÅ«kÅa inhibitora (PSI) kombinÄtÄs terapijas grupa un 3) pankreatÄ«na, PSI un nesteroÄ«dÄ pretiekaisuma lÄ«dzekļa (NSPL) kombinÄtÄs terapijas grupa. PÄtÄ«juma datu analÄ«ze apstiprinÄja, ka KPI ir objektÄ«vs un valÄ«ds instruments HP klÄ«niskÄs gaitas smaguma, medikamentozÄs ÄrstÄÅ”anas efektivitÄtes novÄrtÄÅ”anai un prognozÄÅ”anai. Slimniekiem ar HP VPI atspoguļo ADz strukturÄlo izmaiÅu smagumu un var bÅ«t lietderÄ«gs, prognozÄjot nepiecieÅ”amÄ«bu pÄc Ä·irurÄ£iskÄs ÄrstÄÅ”anas. AnalizÄjot pÄtÄ«juma rezultÄtus, tika secinÄts, ka pankreatÄ«na, PSI un NSPL kombinÄcija ir efektÄ«vÄkÄ HP klÄ«niskÄs gaitas un slimnieku DzK uzlaboÅ”anai, salÄ«dzinot ar pankreatÄ«na monoterapiju un pankreatÄ«na kombinÄciju ar PSI. Pacientiem ar HP mÄnesi ilga pankreatÄ«na, PSI un NSPL kombinÄcijas terapija ir droÅ”a un neizraisa nopietnas blaknes. Å is ir pirmais HP pÄtÄ«jums LatvijÄ un pasaulÄ, kurÄ 1) integrÄli un kvantitatÄ«vi novÄrtÄts HP klÄ«niskÄs gaitas un ADz strukturÄlo izmaiÅu smagums, 2) pielietota HP pankreatÄ«na, PSI un NSPL kombinÄtÄ medikamentozÄ terapija, novÄrtÄjot tÄs efektivitÄti, 3) pirmo reizi LatvijÄ HP slimniekiem dzÄ«ves kvalitÄte novÄrtÄta ar EORTC QLQ ā C30 un QLQ ā PAN26 medikamentozÄs terapijas gadÄ«jumÄ.Promocijas darbs ir izstrÄdÄts ar ESF projekta āAtbalsts doktorantiem studiju programmas apguvei un zinÄtniskÄ grÄda ieguvei RÄ«gas StradiÅa universitÄtÄā atbalstu, vienoÅ”anÄs Nr. 2009/0147/1DP/1.1.2.1.2/09/IPIA/VIAA/009
Assessment of Chronic Pancreatitis Course Severity and Combined Medical Treatment Using Pancreatin, Proton Pump Inhibitor and Non-Steroidal Anti-Inflammatory Drug. Doctoral Thesis
Full text linkPromocijas darbs izstrÄdÄts: RÄ«gas StradiÅa universitÄtes IekŔķīgo slimÄ«bu katedrÄ. AizstÄvÄÅ”ana: 2014. gada 3. novembrÄ« plkst. 15.00 RÄ«gas StradiÅa universitÄtes MedicÄ«nas promocijas padomes atklÄtÄ sÄdÄ RÄ«gÄ, Dzirciema ielÄ 16, HipokrÄta auditorijÄ.Darba mÄrÄ·is ā izstrÄdÄt jaunas hroniska pankreatÄ«ta (HP) klÄ«niskÄs gaitas smaguma un aizkuÅÄ£a dziedzera izmaiÅu smaguma novÄrtÄÅ”anas metodes un, lietojot pankreatÄ«nu monoterapijÄ un kombinÄcijÄ ar protonu sÅ«kÅa inhibitoru, kÄ arÄ« kombinÄjot pankreatÄ«nu, protonu sÅ«kÅa inhibitoru un nesteroÄ«do pretiekaisuma lÄ«dzekli pacientiem ar HP, noskaidrot efektÄ«vÄko no lietotÄs medikamentozÄs ÄrstÄÅ”anas variantiem. ProspektÄ«vÄ randomizÄtÄ kontrolÄtÄ pÄtÄ«jumÄ HP klÄ«niskÄs gaitas un ADz strukturÄlo pÄrmaiÅu smaguma novÄrtÄÅ”anai tika izstrÄdÄtas speciÄlas metodes, izmantojot klÄ«nisko pankreÄtisko indeksu (KPI) un vizuÄlo pankreÄtisko indeksu (VPI). PÄtÄ«juma gaitÄ KPI un VPI tika pielietotas slimniekiem ar HP medikamentozÄs terapijas gadÄ«jumÄ. Slimnieki ar HP, kuriem nebija nepiecieÅ”ama Ä·irurÄ£iskÄ un endoskopiskÄ ÄrstÄÅ”ana, tika sadalÄ«ti trijÄs grupÄs atkarÄ«bÄ no terapijas veida: 1) pankreatÄ«na monoterapijas grupa, 2) pankreatÄ«na un protonu sÅ«kÅa inhibitora (PSI) kombinÄtÄs terapijas grupa un 3) pankreatÄ«na, PSI un nesteroÄ«dÄ pretiekaisuma lÄ«dzekļa (NSPL) kombinÄtÄs terapijas grupa. PÄtÄ«juma datu analÄ«ze apstiprinÄja, ka KPI ir objektÄ«vs un valÄ«ds instruments HP klÄ«niskÄs gaitas smaguma, medikamentozÄs ÄrstÄÅ”anas efektivitÄtes novÄrtÄÅ”anai un prognozÄÅ”anai. Slimniekiem ar HP VPI atspoguļo ADz strukturÄlo izmaiÅu smagumu un var bÅ«t lietderÄ«gs, prognozÄjot nepiecieÅ”amÄ«bu pÄc Ä·irurÄ£iskÄs ÄrstÄÅ”anas. AnalizÄjot pÄtÄ«juma rezultÄtus, tika secinÄts, ka pankreatÄ«na, PSI un NSPL kombinÄcija ir efektÄ«vÄkÄ HP klÄ«niskÄs gaitas un slimnieku DzK uzlaboÅ”anai, salÄ«dzinot ar pankreatÄ«na monoterapiju un pankreatÄ«na kombinÄciju ar PSI. Pacientiem ar HP mÄnesi ilga pankreatÄ«na, PSI un NSPL kombinÄcijas terapija ir droÅ”a un neizraisa nopietnas blaknes. Å is ir pirmais HP pÄtÄ«jums LatvijÄ un pasaulÄ, kurÄ 1) integrÄli un kvantitatÄ«vi novÄrtÄts HP klÄ«niskÄs gaitas un ADz strukturÄlo izmaiÅu smagums, 2) pielietota HP pankreatÄ«na, PSI un NSPL kombinÄtÄ medikamentozÄ terapija, novÄrtÄjot tÄs efektivitÄti, 3) pirmo reizi LatvijÄ HP slimniekiem dzÄ«ves kvalitÄte novÄrtÄta ar EORTC QLQ ā C30 un QLQ ā PAN26 medikamentozÄs terapijas gadÄ«jumÄ.Promocijas darbs ir izstrÄdÄts ar ESF projekta āAtbalsts doktorantiem studiju programmas apguvei un zinÄtniskÄ grÄda ieguvei RÄ«gas StradiÅa universitÄtÄā atbalstu, vienoÅ”anÄs Nr. 2009/0147/1DP/1.1.2.1.2/09/IPIA/VIAA/009
